Evolve Formulas Transdermal NanoSerum™ CBD Met with Unprecedented Response across Colorado Market
November 7, 2018
—Industry-First Formulation Harnesses the Anti-Inflammatory Qualities
of CBD and Antioxidant Power of Resveratrol for Maximum Wellness
Benefits—
DENVER, Colo.–(BUSINESS WIRE)–NanoSphere
Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF), the biotechnology
leader behind the patented NanoSphere Delivery System™, today announced
the expansion of its CBD-dominant product—the Evolve
Formulas Transdermal NanoSerum™ CBD with Resveratrol—across
Colorado due to considerable public demand. The company has already
moved more than 1,000 units in the market in less than a month.
The Evolve Formulas Transdermal NanoSerum™ CBD utilizes a combination
formula of synergistic cannabinoids, with each precision-metered dose
containing 15mg of CBD and 1.5mg of THC. In addition, the unique,
research-backed scientific formulation includes terpenes and resveratrol
for maximum therapeutic benefit. Studies show that CBD can aid in
relieving inflammation, anxiety, pain and insomnia, while restorative
ingredient resveratrol is lauded in the health, wellness and beauty
worlds for its antioxidant, neuroprotective, anti-aging and cognitive
enhancement benefits. The new item has been met with an overwhelmingly
positive response from consumers across the state.
“NanoSphere takes great pride in developing world-class offerings that
not only utilize our cutting edge, patented technology, but that include
thoughtful formulations with the consumer in mind. Our goal is to
deliver unparalleled relief and ensure customers receive the most
consistent, trustworthy and effective product possible,” said Robert
Sutton, Chairman and CEO of NanoSphere Health Sciences and Evolve
Formulas. “Seeing the public’s tremendous response to our CBD-dominant
NanoSerum™ has been nothing short of rewarding, motivating us to
continue innovating and expanding our industry-leading solutions across
the state, country and continent.”
“As a mom of two toddlers, my days are hectic and long, and unwinding at
night is a challenge. I am thinking of all the tasks that tomorrow will
bring—so getting to sleep has been difficult for me. Now, I use Evolve’s
CBD and it’s fantastic. It reduces my stress and anxiety and helps me
get a full night’s rest,” said Kelly S., Evolve Formulas customer.
“Plus, it’s natural and there are no side effects. Honestly, I don’t
think there’s a better product out there for me.”
The Transdermal NanoSerum™ CBD is now available in 40 of the 200
total dispensaries that Evolve Formulas products are currently in across
the state, including all Lucy
Sky Cannabis Boutique locations. Within the next month, the CBD
product is expected to be in all 200 dispensaries.
For more information on Nanosphere Health Sciences, Inc. or to schedule
an interview, please contact Gabrielle Wesseldyk at media@nanospherehealth.com
or 212-255-0945.
NanoSphere’s Commitment to Licensing IP
NanoSphere launched its IP licensing program in 2015 and is entertaining
several licensing opportunities via a rigorous evaluation process. For
more information about NanoSphere’s licensing program, please visit: https://www.nanospherehealth.com/licensing/
About NanoSphere
NanoSphere Health Sciences, Inc. is a biotechnology firm specializing in
the creation of the patented NanoSphere Delivery System™, a
revolutionary platform using nanotechnology in the biodelivery of
supplements, nutraceuticals and over-the-counter medications for the
cannabis, pharmaceutical and animal health industries, and beyond.
Covered by U.S. Patent No. 10,028,919 and U.S. Patent No. 9,925,149,
NanoSphere Delivery System™ represents one of the most important
developments for advancing the non-invasive and user-friendly delivery
of biological agents in over 25 years. NanoSphere was awarded the 2018
Frost and Sullivan Technology Innovation Award and was recognized by
ACQ5 Global Awards as Company of the Year for Nano-Biotechnology,
Innovative Company of the Year for Healthcare, and its CEO Robert Sutton
was honored as Gamechanger of the Year. For more information on
NanoSphere, please visit http://www.nanospherehealth.com.
About Evolve Formulas
Evolve Formulas is the provider of the world’s first and only
scientifically proven nanoparticle delivery system in cannabis. Evolve’s
pioneering product, Transdermal NanoSerum™, is a fast-acting,
ultra-strength transdermal formula infused with nano-encapsulated
cannabis and cannabis extracts. NanoSerum™ immediately penetrates the
skin to deliver direct-focused results and intelligently carries a full
spectrum of cannabinoids and phytochemicals to receptors throughout the
body for systemic healing. Evolve Formula products leverage NanoSphere
Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere
Delivery System™ is a revolutionary platform using nanotechnology in the
biodelivery of supplements, nutraceuticals and over-the-counter
medications for the cannabis, pharmaceutical and animal health
industries, and beyond. For more information on Evolve Formulas, visit https://www.evolveformulas.com/.
Follow us on Facebook,
Instagram
and Twitter.
The Canadian Securities Exchange does not accept responsibility for
the adequacy or accuracy of this release.
Forward Looking Statement Caution
This news release includes forward looking statements that are
subject to assumptions, risks and uncertainties. Statements in this news
release which are not purely historical are forward looking statements,
including without limitation any statements concerning the Company’s
intentions, plans, estimates, expectations or beliefs regarding the
future. Although the Company believes that any forward looking
statements in this news release are reasonable, there can be no
assurance that any such forward looking statements will prove to be
accurate. The Company cautions readers that all forward looking
statements, including without limitation those relating to the Company’s
future operations and business prospects, are based on assumptions none
of which can be assured, and are subject to certain risks and
uncertainties that could cause actual events or results to differ
materially from those indicated in the forward looking statements.
Readers are advised to rely on their own evaluation of such risks and
uncertainties and should not place undue reliance on forward looking
statements. Any forward looking statements are made as of the date of
this news release, and the Company assumes no obligation to update the
forward looking statements, or to update the reasons why actual events
or results could or do differ from those projected in the forward
looking statements, whether as a result of new information, future
events or otherwise.
Contacts
NanoSphere Health Sciences, Inc.
On behalf of the Board
Robert
Sutton, 720-520-4282
Chairman and CEO
rsutton@nanospherehealth.com
or
Investor
Contact:
Victor Goncalves, 204-997-5517
Executive Vice
President
vgoncalves@nanospherehealth.com
or
The
Rosen Group
Gabrielle Wesseldyk, 212-255-0945
gabrielle@rosengrouppr.com